BARBARA IZZO
- Type
- Persona (Classe)
- Label
- BARBARA IZZO (literal)
- BARBARA IZZO (literal)
- Subject
- Diseases and disorders (Categoria DBpedia)
- Hematology (Categoria DBpedia)
- Leukemia (Categoria DBpedia)
- Blood disorders (Categoria DBpedia)
- Types of cancer (Categoria DBpedia)
- Partecipa a commessa
- Partecipazione a Commessa "Imaging Molecolare in Oncologia, Sintesi di Molecole Radiomarcate e Sviluppo di Approcci Diagnostici e Terapeutici Innovativi" (ME.P03.001) di DOTT.SSA BARBARA IZZO nell'anno 2007 (Partecipazione a commessa)
- Partecipazione a Commessa "Imaging Molecolare in Oncologia, Sintesi di Molecole Radiomarcate e Sviluppo di Approcci Diagnostici e Terapeutici Innovativi" (ME.P03.001) di DOTT.SSA BARBARA IZZO nell'anno 2008 (Partecipazione a commessa)
- Persona in rapporto
- Rapporto con CNR di DOTT.SSA BARBARA IZZO (Rapporto con CNR)
- Autore CNR di
- Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Significant reduction of the hybrid BCR/ABL transcripts after inducyion and consolidation therapy is a powerful predictor of tratmnt response in adult Philadelphia-positive acute lymbophoblastic leukemia (Articolo in rivista) (Prodotto della ricerca)
- REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH+ CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT (Abstract in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1105)
- The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial (Abstract in rivista) (Prodotto della ricerca)
- ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of pregression to blast crisis and shorter survilval: a study by the GIMEMA Working Party (Articolo in rivista) (Prodotto della ricerca)
- Contribution of ABL kinase domain mutation to imatinib resistance in different subsets of Philadelphia-positive patients: by the GINEMA working party on Chronic Myeloid Leukemia (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients (Abstract in rivista) (Prodotto della ricerca)
- FLT3 MUTATIONS IN MLL-REARRANGED INFANT ACUTE LYMPHOBLASIC LEUKEMIA (ALL): EXPERIENCE OF A SINGLE PEDIATRIC INSTITUTION (Abstract in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1105)
- A decreased Level of Shp1 provides an additive survival advantage to the Ph plus Cells of CML Patients and may account for Resistance to Imatinib Treatment (Abstract in rivista) (Prodotto della ricerca)
- Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study (Articolo in rivista) (Prodotto della ricerca)
- Coautore
- MARIO QUARANTELLI (Unità di personale interno)
- MARCELLO MANCINI (Persona)
- Nome
- BARBARA (literal)
- Cognome
- IZZO (literal)
- Afferisce a
- Ha pubblicazioni con
- MARCELLO MANCINI (Persona)
- Http://www.cnr.it/ontology/persone.owl#argomentoDiRicercaSimile
- MARCELLO MANCINI (Persona)
Incoming links:
- Coautore
- MARCELLO MANCINI (Persona)
- MARIO QUARANTELLI (Unità di personale interno)
- Ha pubblicazioni con
- MARCELLO MANCINI (Persona)
- Http://www.cnr.it/ontology/persone.owl#argomentoDiRicercaSimile
- MARCELLO MANCINI (Persona)
- Partecipazione di
- Partecipazione a Commessa "Imaging Molecolare in Oncologia, Sintesi di Molecole Radiomarcate e Sviluppo di Approcci Diagnostici e Terapeutici Innovativi" (ME.P03.001) di DOTT.SSA BARBARA IZZO nell'anno 2008 (Partecipazione a commessa)
- Partecipazione a Commessa "Imaging Molecolare in Oncologia, Sintesi di Molecole Radiomarcate e Sviluppo di Approcci Diagnostici e Terapeutici Innovativi" (ME.P03.001) di DOTT.SSA BARBARA IZZO nell'anno 2007 (Partecipazione a commessa)
- Ha afferente
- Rapporto con persona
- Rapporto con CNR di DOTT.SSA BARBARA IZZO (Rapporto con CNR)
- Autore CNR
- Prognostic impact of genetic characterization in the GIMEMA LAM99P multicenter study for newly diagnosed acute myeloid leukemia (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- ABL mutations in late chronic phase chronic myeloid leukemia patients with up-front cytogenetic resistance to imatinib are associated with a greater likelihood of pregression to blast crisis and shorter survilval: a study by the GIMEMA Working Party (Articolo in rivista) (Prodotto della ricerca)
- Myeloablative chemotherapy followed by autologous stem cell infusion may overcome the adverse prognostic impact of FLT3 (foetal liver tyrosine kinase 3) mutations in patients with acute myeloid leukaemia and normal karyotype (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Presence of FLT3 mutations does not impair stem cell mobilization and feasibility of autologous peripheral blood stem cell transplantation in acute myeloid leukemia (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Achieving a major molecular response at the time of a complete cytogenetic response (CCgR) predicts a better duration of CCgR in imatinib-treated chronic myeloid leukemia patients (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Significant reduction of the hybrid BCR/ABL transcripts after inducyion and consolidation therapy is a powerful predictor of tratmnt response in adult Philadelphia-positive acute lymbophoblastic leukemia (Articolo in rivista) (Prodotto della ricerca)
- Contribution of ABL kinase domain mutation to imatinib resistance in different subsets of Philadelphia-positive patients: by the GINEMA working party on Chronic Myeloid Leukemia (Articolo in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1101)
- Real-Time Quantitative Polymerase Chain Reaction Detection of Minimal Residual Disease by Standardized WT1 Assay to Enhance Risk Stratification in Acute Myeloid Leukemia: A European LeukemiaNet Study (Articolo in rivista) (Prodotto della ricerca)
- The Expression of shp-1 and SHP-2: A Novel Powerful Predictor of Major Molecular Response (MMR) Achievement in Chronic Myeloid Leukemia Gleevec-Treated Patients Enrolled into the TOPS Clinical Trial (Abstract in rivista) (Prodotto della ricerca)
- REDUCED LEVELS OF SHP1 PROVIDES AN ADDITIVE SURVIVAL ADVANTAGE TO THE PH+ CELLS OF CML PATIENTS AND MAY ACCOUNT FOR RESISTANCE TO IMA TREATMENT (Abstract in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1105)
- A decreased Level of Shp1 provides an additive survival advantage to the Ph plus Cells of CML Patients and may account for Resistance to Imatinib Treatment (Abstract in rivista) (Prodotto della ricerca)
- FLT3 MUTATIONS IN MLL-REARRANGED INFANT ACUTE LYMPHOBLASIC LEUKEMIA (ALL): EXPERIENCE OF A SINGLE PEDIATRIC INSTITUTION (Abstract in rivista) (http://www.cnr.it/ontology/cnr/individuo/prodotto/TIPO1105)
- Reduced Expression Level of SHP1 Gives An Additive Survival Advantage to the Ph plus Cells of Chronic Myeloid Leukemia (CML) Patients and Provides a Novel Pretreatment Predictor of Major Molecular Response Achievement in CML Patients (Abstract in rivista) (Prodotto della ricerca)
- Http://www.w3.org/2004/02/skos/core#isSubjectOf
- Leukemia (Categoria DBpedia)
- Diseases and disorders (Categoria DBpedia)
- Hematology (Categoria DBpedia)
- Blood disorders (Categoria DBpedia)
- Types of cancer (Categoria DBpedia)